Selexipag and the pulmonary hypertension continuum
- PMID: 34816552
- DOI: 10.1002/ejhf.2387
Selexipag and the pulmonary hypertension continuum
Comment on
-
The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study.Eur J Heart Fail. 2022 Jan;24(1):205-214. doi: 10.1002/ejhf.2369. Epub 2021 Nov 21. Eur J Heart Fail. 2022. PMID: 34806261 Free PMC article. Clinical Trial.
References
-
- Maeder MT, Schoch OD, Kleiner R, Joerg L, Weilenmann D; Swiss Society for Pulmonary Hypertension. Pulmonary hypertension associated with left-sided heart disease. Swiss Med Wkly. 2017;147:w14395.
-
- Maeder MT, Weber L, Buser M, Brenner R, Joerg L, Rickli H. Pulmonary hypertension in patients with heart failure with mid-range ejection fraction. Front Cardiovasc Med. 2021;8:694240.
-
- Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451-61.
-
- Burkhoff D, Borlaug BA, Shah SJ, Zolty R, Tedford RJ, Thenappan T, et al. Levosimendan improves hemodynamics and exercise tolerance in PH-HFpEF: results of the randomized placebo-controlled HELP trial. JACC Heart Fail. 2021;9:360-70.
-
- Borlaug BA, Obokata M. Is it time to recognize a new phenotype? Heart failure with preserved ejection fraction with pulmonary vascular disease. Eur Heart J. 2017;38:2874-8.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical